Overview Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients Status: Recruiting Trial end date: 2025-03-01 Target enrollment: Participant gender: Summary Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib Phase: Phase 2 Details Lead Sponsor: Hutchison Medipharma Limited